Clinical Trials » Retinitis Pigmentosa
Brimonidine Intravitreal Implant for Retinitis Pigmentosa: Allergan
|
NOT RECRUITING Description: Allergan conducted a Phase I clinical trial of brimonidine tartrate, delivered through an intravitreal implant, for the treatment of retinitis pigmnetosa (RP). The study, conducted in Eurpoe and the U.S., included approximately 25 participants. Three different doses of the drug were evaluated. Known as the posterior segment drug delivery system, the intravitreal implant provided sustained delivery of the drug to the back of the eye. Brimonidine is a drug approved by the FDA for the treatment of glaucoma. In prior clinical evaluations, the drug showed potential for slowing vision loss in people with RP and related animal models. Trial Status: Completed; awaiting report of results. Articles: Glaucoma drug brimonidine moving into clinical trials for RP, AMD Additional Information: Brimonidine clinical trial for RP listing on ClinicalTrails.gov |
